Caris Life Sciences, Inc. (CAI) – What Are Brokerages Thinking About This Stock?

Shares of Caris Life Sciences, Inc. (NASDAQ:CAI) have been given an average recommendation of “Moderate Buy” by the fourteen brokerages that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and eight have issued a buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $28.55.

Several equities research analysts recently weighed in on CAI shares. UBS Group initiated coverage on Caris Life Sciences in a research note on Wednesday, September 9th. They issued a “neutral” rating and a $28.00 price target on the stock. BTIG Research increased their price objective on Caris Life Sciences from $32.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Canaccord Genuity Group raised their price objective on Caris Life Sciences from $22.00 to $30.00 and gave the company a “hold” rating in a research report on Monday, October 19th. Wall Street Zen upgraded shares of Caris Life Sciences from a “sell” rating to a “hold” rating in a report on Sunday, August 16th. Finally, TD Cowen boosted their target price on shares of Caris Life Sciences from $30.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, October 13th.

Insider Activity at Caris Life Sciences

In other Caris Life Sciences news, insider John Russel Denton sold 7,500 shares of the company’s stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $31.82, for a total value of $238,650.00. Following the sale, the insider owned 174,855 shares in the company, valued at approximately $5,563,886.10. This represents a 4.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, President David Spetzler sold 478,000 shares of the company’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $24.86, for a total transaction of $11,883,080.00. Following the completion of the sale, the president owned 1,052,083 shares in the company, valued at approximately $26,154,783.38. This trade represents a 31.24% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 1,004,712 shares of company stock valued at $27,205,419 in the last three months. Company insiders own 50.00% of the company’s stock.

Institutional Trading of Caris Life Sciences

A number of hedge funds have recently made changes to their positions in the stock. Citizens Financial Group Inc. RI purchased a new stake in shares of Caris Life Sciences in the 3rd quarter worth approximately $475,000. MBL Wealth LLC bought a new position in Caris Life Sciences during the 3rd quarter valued at approximately $222,000. Root Financial Partners LLC purchased a new position in Caris Life Sciences during the third quarter valued at $60,000. E. Ohman J or Asset Management AB purchased a new position in Caris Life Sciences during the third quarter valued at $3,829,000. Finally, IFP Advisors Inc raised its stake in Caris Life Sciences by 143,800.0% during the third quarter. IFP Advisors Inc now owns 4,317 shares of the company’s stock valued at $132,000 after buying an additional 4,314 shares during the last quarter.

Caris Life Sciences Stock Up 0.9%

Shares of NASDAQ:CAI opened at $32.00 on Friday. Caris Life Sciences has a 52-week low of $14.19 and a 52-week high of $33.13. The firm has a market capitalization of $9.04 billion, a P/E ratio of 88.89 and a beta of 0.86. The stock has a 50 day moving average price of $28.02 and a 200-day moving average price of $21.38. The company has a debt-to-equity ratio of 0.66, a quick ratio of 4.88 and a current ratio of 5.53.

About Caris Life Sciences

Caris Life Sciences is a biotechnology and precision-medicine company that uses molecular profiling and artificial intelligence to support cancer diagnosis, treatment selection and drug development. The company analyzes tumor and blood samples to identify genomic, molecular and immune characteristics that may help physicians better understand a patient’s disease and select targeted therapies.

Its offerings include comprehensive tumor profiling, liquid-biopsy testing and data-driven clinical decision-support tools.